175 related articles for article (PubMed ID: 8738588)
21. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
[TBL] [Abstract][Full Text] [Related]
22. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Boström SL; Hansson GF; Sarich TC; Wolzt M
Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of recombinant hirudin in healthy horses.
Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
[TBL] [Abstract][Full Text] [Related]
24. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
25. Effects of two different doses of hirudin on APTT, determined with eight different reagents.
Monreal M; Monreal L; Ruiz de Gopegui R; Espada Y; Angles AM; Monasterio J
Thromb Haemost; 1995 Feb; 73(2):219-22. PubMed ID: 7792733
[TBL] [Abstract][Full Text] [Related]
26. Antithrombin effects of native and recombinant hirudins.
Markwardt F; Stürzebecher J; Glusa E
Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
Cannon CP; Maraganore JM; Loscalzo J; McAllister A; Eddings K; George D; Selwyn AP; Adelman B; Fox I; Braunwald E
Am J Cardiol; 1993 Apr; 71(10):778-82. PubMed ID: 8456753
[TBL] [Abstract][Full Text] [Related]
28. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
Moser M; Ruef J; Peter K; Kohler B; Gulba DC; Paterna N; Nordt T; Kübler W; Bode C
J Thromb Thrombolysis; 2001 Oct; 12(2):165-9. PubMed ID: 11729368
[TBL] [Abstract][Full Text] [Related]
29. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
Tripodi A; Chantarangkul V; Arbini AA; Moia M; Mannucci PM
Thromb Haemost; 1993 Aug; 70(2):286-8. PubMed ID: 8236136
[TBL] [Abstract][Full Text] [Related]
30. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
[TBL] [Abstract][Full Text] [Related]
31. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
[TBL] [Abstract][Full Text] [Related]
32. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
[TBL] [Abstract][Full Text] [Related]
33. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
34. RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection.
Li YR; Huang YN; Zhao B; Wu MF; Li TY; Zhang YL; Chen D; Yu M; Mo W
Acta Pharmacol Sin; 2020 Jun; 41(6):753-762. PubMed ID: 31949293
[TBL] [Abstract][Full Text] [Related]
35. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers.
Gou ZP; Song ZH; Chen XG; Hu XC; Wang Y; Fan K; Cai YM; Zheng L
CNS Drugs; 2019 Jun; 33(6):605-614. PubMed ID: 31093952
[TBL] [Abstract][Full Text] [Related]
36. Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin.
Harenberg J; Hoffmann U; Huhle G; Song XH; Wang LC
Br J Haematol; 2000 Mar; 108(3):528-30. PubMed ID: 10759710
[TBL] [Abstract][Full Text] [Related]
37. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL
Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
Pötzsch B; Hund S; Madlener K; Unkrig C; Müller-Berghaus G
Thromb Res; 1997 Jun; 86(5):373-83. PubMed ID: 9211628
[TBL] [Abstract][Full Text] [Related]
39. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.
Walenga JM; Bakhos M; Messmore HL; Koza M; Wallock M; Orfei E; Fareed J; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):105-11. PubMed ID: 1772977
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
Zhang B; Wieslander JB
Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]